Forging Ahead the Repositioning of Multitargeted Drug Ivermectin (2023)

Peer-Reviewed Study · Atmakuri S; Nene S; Khatri D; Singh SB; Sinha VR; Srivastava S · 2023

Atmakuri S et al., 2023: Review of ivermectin's repositioning beyond parasitic disease, covering cancer, viral and bacterial indications, plus regulatory considerations and formulation strategies for repurposing.

The current review highlights its role in unexplored avenues towards forging ahead of the repositioning of this multitargeted drug in cancer, viral (the evaluation of the efficacy of ivermectin against SARS-Cov-2 is under investigation) and bacterial infection and malaria.

n/a (PubMed abstract)

Atmakuri S et al., 2023: Review of ivermectin's repositioning beyond parasitic disease, covering cancer, viral and bacterial indications, plus regulatory considerations and formulation strategies for repurposing. Study type: narrative review. N: not stated. Country: India (NIPER Hyderabad). Dose/route/schedule: n/a. Funder/COI: not stated in the PubMed record. Comparator: n/a. Quote is one continuous sentence from the abstract (parenthetical retained). Study type: review.